Generated by All in One SEO Pro v4.9.6, this is an llms.txt file, used by LLMs to index the site.

# Scipher Medicine

Advancing Precision Medicine for Autoimmune Diseases

## Sitemaps

- [XML Sitemap](https://www.sciphermedicine.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Latest](https://www.sciphermedicine.com/latest/)
- [Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis](https://www.sciphermedicine.com/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce/) - [et_pb_section fb_built=”1″ _builder_version=”4.27.4″ global_colors_info=”{}” theme_builder_area=”initial_post_content” custom_padding=”1px|||||”][et_pb_row _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”initial_post_content” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false” width=”100%” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”4.27.4″ custom_padding=”0px|0px|0px|0px|false|false” hover_enabled=”0″ global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”initial_post_content” sticky_enabled=”0″][et_pb_text _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”initial_post_content” sticky_enabled=”0″ custom_css_free_form=”||.scipher-press-release {|| max-width: 920px;|| margin: 0 auto;|| color: #1f1a2d;|| font-family: inherit;|| font-size: 16px;|| line-height: 1.62;||}||.scipher-press-release p {|| margin: 0 0 18px;|| padding:
- [Scipher Medicine Shares Published Data Further Validating RA Patient Outcome Improvement With PrismRA Testing](https://www.sciphermedicine.com/scipher-medicine-shares-published-data-further-validating-ra-patient-outcome-improvement-with-prismra-testing/) - [et_pb_section fb_built=”1″ _builder_version=”4.27.4″ hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”]FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them.” ~ Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ — Scipher Medicine, a leader in
- [Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development](https://www.sciphermedicine.com/spectra-target-discovery-platform-de-risks-investment-decisions-by-predicting-avoidable-clinical-trial-failures-2/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 — Scipher Medicine and Senelix today announced a strategic collaboration to incorporate
- [Spectra™ Target Discovery Platform De-Risks Investment Decisions by Predicting Avoidable Clinical Trial Failures](https://www.sciphermedicine.com/spectra-target-discovery-platform-de-risks-investment-decisions-by-predicting-avoidable-clinical-trial-failures/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Drug discovery and development remains one of the most challenging and resource-intensive processes in modern medicine. With development timelines spanning 10-15 years and costs exceeding $1-3 billion per approved drug1, the
- [Scipher Medicine and Maxymune Therapeutics Announce Strategic Collaboration to Accelerate Target Discovery in Autoimmune and Inflammatory Diseases](https://www.sciphermedicine.com/scipher-medicine-and-maxymune-therapeutics-announce-strategic-collaboration-to-accelerate-target-discovery-in-autoimmune-and-inflammatory-diseases/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] BURLINGTON, Mass.–(BUSINESS WIRE)–Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research
- [Scipher Medicine Launches ClinicalTrialRank.com: A Breakthrough AI Platform to Predict Clinical Trial Failure and Revolutionize Drug Development Investment Strategy](https://www.sciphermedicine.com/scipher-medicine-launches-clinicaltrialrank-com-a-breakthrough-ai-platform-to-predict-clinical-trial-failure-and-revolutionize-drug-development-investment-strategy/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical
- [Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis](https://www.sciphermedicine.com/scipher-and-savant-bio-partner-to-build-the-most-comprehensive-clinico-genomic-dataset-in-rheumatoid-arthritis/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] NEW YORK & WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic
- [Scipher Medicine Unveils New Tool to Predict Rheumatoid Arthritis Treatment Success at EULAR 2025](https://www.sciphermedicine.com/scipher-medicine-unveils-new-tool-to-predict-rheumatoid-arthritis-treatment-success-at-eular-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] Novel “RA Response Calculator” Uses AI and Real Patient Data to Help Doctors Better Tailor Treatment Plans WALTHAM, MA – June 18, 2025 – At the
- [Scipher Medicine expands its global presence, bringing precision medicine to Latin America through its alliance with Grupo Amarey](https://www.sciphermedicine.com/scipher-medicine-expands-its-global-presence-bringing-precision-medicine-to-latin-america-through-its-alliance-with-grupo-amarey/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] WALTHAM, Massachusetts – June 16, 2025 Scipher Medicine, a leading precision immunology company, today announced a strategic alliance with Grupo Amarey, a leading company in the
- [Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design](https://www.sciphermedicine.com/collaboration-to-integrate-precision-medicine-into-clinical-trial-design/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content” custom_padding=”||0px|||”] Partnership integrates Scipher’s PrismRA to deliver insights into therapy response segmentation WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today
- [Scipher Medicine and InnoSIGN Announce Partnership to Advance Precision Medicine in Immunology](https://www.sciphermedicine.com/scipher-medicine-and-innosign-announce-partnership-to-advance-precision-medicine-in-immunology/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] Collaboration combines Scipher’s unique RNAseq data, part of the largest non-oncology clinico-transcriptomic data lake and biobank, with InnoSIGN’s proprietary Comprehensive Pathway Analysis (CPA) platform to enhance the
- [Scipher Medicine and Kythera Labs Partner to Unlock New Insights into Autoimmune Disease-Specific Treatment](https://www.sciphermedicine.com/scipher-medicine-and-kythera-labs-partner-to-unlock-new-insights-into-autoimmune-disease-specific-treatment/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] The partnership integrates Kythera’s enriched high-fidelity multi-source EHR and claims data assets with real-world clinical and genomic data from Scipher’s PrismRA® Test, revealing new insights for precision
- [Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development](https://www.sciphermedicine.com/scipher-medicine-and-roivant-partner-to-bring-precision-medicine-insights-to-rheumatology-drug-discovery-and-development/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”] Waltham, MA – Jan. 13, 2025 – Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives
- [OMNY Health and Scipher Medicine Partner to Revolutionize Autoimmune Disease Treatment with Clinico-Transcriptomics Data ](https://www.sciphermedicine.com/omny-health-and-scipher-medicine-partner-to-revolutionize-autoimmune-disease-treatment-with-clinico-transcriptomics-data/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”] The partnership integrates transcriptome genomic data from Scipher’s PrismRA Test into OMNY’s EMR network, unlocking deeper patient insights for precision medicine advancements. Atlanta, Georgia – Jan. 9, 2025 –
- [Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network ](https://www.sciphermedicine.com/scipher-medicine-and-atropos-health-partner-to-accelerate-precision-medicine-and-expand-the-immunology-multimodal-network/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] WALTHAM, Mass., December 18, 2024 Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Atropos Health, the pioneer in translating real-world clinical data into personalized
- [Scipher Medicine® Launches a New Approach to Discover Treatment-Response-Predicting Biomarkers for Complex Diseases](https://www.sciphermedicine.com/scipher-medicine-launches-a-new-approach-to-discover-treatment-response-predicting-biomarkers-for-complex-diseases/) - WALTHAM, Mass., July 30, 2024 Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, has launched a new approach to develop biomarkers following the publication of the novel, patent-pending framework PRoBeNet (Predictive Response Biomarkers using Network medicine). “I am thrilled to be launching PRoBeNet to enable an
- [A network-based framework to discover treatment-response-predicting biomarkers for complex diseases](https://www.sciphermedicine.com/a-network-based-framework-to-discover-treatment-response-predicting-biomarkers-for-complex-diseases/) - Uday Shankar Shanthamallu, Casey Kilpatrick, Alex Jones, Jonathan Rubin, Alif Saleh, Albert-László Barabási, Viatcheslav R. Akmaev, Susan Dina Ghiassian ABSTRACT Precision medicine's potential to transform complex autoimmune-disease treatment is often challenged by limited data availability and inadequate sample size when compared to the number of molecular features found in high-throughput multi-omics datasets. Addressing this issue,
- [Scipher Medicine® Showcases New Data at EULAR 2024](https://www.sciphermedicine.com/scipher-medicine-showcases-new-data-at-eular-2024/) - WALTHAM, Mass., June 13, 2024 Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in Vienna, Austria. The poster presentation highlighted the impact PrismRA is having on the use of biologic and
- [Identifying TNFI Therapy Response in UC Patients Using Baseline Whole Blood Gene Expression Data](https://www.sciphermedicine.com/identifying-tnfi-therapy-response-in-uc-patients-using-baseline-whole-blood-gene-expression-data/) - Shanthamallu, Uday Shankar ; Jones, Alexander ; Panés, Julián ; Corraliza Márquez, Ana Maria ; Salas, Azucena ; Akmaev, Slava ; Ghiassian, Susan Dina Background Non-response to TNF inhibitor (TNFi) therapies remains a challenge in UC/IBD management. Identification of non-responders before initiating biologic therapy can reduce costs and bolster the principles of precision medicine. In
- [Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth ](https://www.sciphermedicine.com/dr-reginald-seeto-appointed-as-ceo-and-president-to-lead-scipher-medicines-next-phase-of-growth/) - WALTHAM, Mass., May 9, 2024 Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President. Scipher developed SpectraTM, a proprietary AI platform that has been used to build both an autoimmune diagnostic and an emerging biopharmaceutical business. In the diagnostics business, PrismRA® was recently
- [A new test could save arthritis patients time, money and pain. But will it be used?](https://www.sciphermedicine.com/a-new-test-could-save-arthritis-patients-time-money-and-pain-but-will-it-be-used/) - NPR SAN DIEGO — Dr. Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn't responded to Enbrel or Humira, two drugs in the same class. But the insurer insisted, so Schulte went on Remicade. It didn't
- [‘A ton of hurdles’ stand in the way of precision medicine for rheumatoid arthritis](https://www.sciphermedicine.com/a-ton-of-hurdles-stand-in-the-way-of-precision-medicine-for-rheumatoid-arthritis/) - Healio The slow march toward precision medicine in rheumatoid arthritis features increased use of serum biomarkers and novel approaches to biopsy, but “a ton of hurdles” remain, according to a presenter at the Biologic Therapies Summit. “We have been struggling for years to advance RA therapeutics toward more precision medicine,” Stanley Cohen, MD, clinical professor in the department
- [Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis](https://www.sciphermedicine.com/decision-impact-analysis-to-measure-the-influence-of-molecular-signature-response-classifier-testing-on-treatment-selection-in-rheumatoid-arthritis/) - Jeffrey R Curtis 1, Vibeke Strand 2, Steven J Golombek 3, George A Karpouzas 4 5, Lixia Zhang 6, Angus Wong 6, Krishna Patel 6, Jennifer Dines 6, Viatcheslav R Akmaev 7 Introduction: Clinical guidelines offer little guidance for treatment selection following inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARD) in rheumatoid arthritis (RA). A molecular signature response classifier (MSRC) was validated to predict tumor necrosis factor inhibitor (TNFi) inadequate response. The
- [Confronting Step Therapy in Rheumatoid Arthritis: A Rheumatology Practice's Experience Using PrismRA to Bypass Ineffective TNF Inhibitor Therapies](https://www.sciphermedicine.com/confronting-step-therapy-in-rheumatoid-arthritis-a-rheumatology-practices-experience-using-prismra-to-bypass-ineffective-tnf-inhibitor-therapies/) - John Boone, Gary Crump and Rosie Walters Introduction Step Therapy (ST), also known as “Step Edit” or “Fail First”, is a policy adopted by third-party payers to minimize costs of prescription drug use by requiring patients to trial a less expensive, first-line medication before second-or third-line options are reimbursed by a patient’s health plan [1].
- [Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry](https://www.sciphermedicine.com/patient-perceptions-of-rheumatoid-arthritis-blood-work-a-cross-sectional-survey-in-the-arthritispower-registry/) - William Nowell1, Shilpa Venkatachalam2, Kelly Gavigan1, Michael George3, Johanna Withers4, Laura Stradford5, Esteban Rivera1 and Jeffrey Curtis6, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, New York, NY, 3University of Pennsylvania, Philadelphia, PA, 4Scipher Medicine Corportaion, Waltham, MA, 5Global Healthy Living Foundation, Nyack, NY, 6Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL Background/Purpose: Although
- [Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)](https://www.sciphermedicine.com/decreased-discontinuation-and-switching-of-b-tsdmard-therapy-in-ra-patients-when-treatment-is-aligned-with-a-molecular-signature-response-classifier-an-analysis-from-the-study-to-accelerate-informati/) - Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or validated biomarkers
- [Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)](https://www.sciphermedicine.com/patient-reported-outcomes-in-rheumatoid-arthritis-correlate-with-clinical-disease-activity-index-response-in-the-study-to-accelerate-information-of-molecular-signatures-aims/) - Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a broader conceptualization
- [Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis](https://www.sciphermedicine.com/improvement-in-clinical-disease-activity-index-when-treatment-selection-is-informed-by-the-tumor-necrosis-factor-a-inhibitor-molecular-signature-response-classifier-analysis-from-the-study-to-acceler/) - Vibeke Strand; Lixia Zhang; Alix Arnaud; Erin Connolly-Strong; Sam Asgarian & Johanna B Withers Background A blood-based molecular signature response classifier (MSRC) predicts non-response to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA). Research design and methods This is an interim analysis of data collected in the Study to Accelerate Information of Molecular Signatures
- [Spectra Logo](https://www.sciphermedicine.com/spectra-logo/) - Download
- [PrismRA Logo - White](https://www.sciphermedicine.com/prismra-logo-white/) - Download
- [PrismRA Logo - Black](https://www.sciphermedicine.com/prismra-logo-black/) - Download
- [Scipher Medicine Logo - White](https://www.sciphermedicine.com/scipher-medicine-logo-white/) - Scipher-Logo-White-1Download
- [Scipher Medicine - Corporate Logo](https://www.sciphermedicine.com/scipher-medicine-corporate-logo/) - Download
- [Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference](https://www.sciphermedicine.com/scipher-medicine-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference/) - WALTHAM, Mass. (Feb. 11, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Chief Financial Officer John Strumbos will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, hosting investor meetings on Tuesday, February 15. About Scipher Medicine® Scipher Medicine, a precision immunology company matching each
- [RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care](https://www.sciphermedicine.com/rxparadigm-partners-with-scipher-medicine-to-support-medication-utilization-improve-patient-outcomes-and-lower-costs-for-rheumatoid-arthritis-care/) - November 15, 2021 - WALTHAM, Mass. - Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to PrismRA. PrismRA is the only molecular signature blood test
- [Scipher Medicine<sup>®</sup> to Present at the Jeffries London Healthcare Conference](https://www.sciphermedicine.com/scipher-medicine-to-present-at-the-jeffries-london-healthcare-conference/) - November 11, 2021 - WALTHAM, Mass. - Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer, will participate in the Jeffries London Healthcare Conference, November 16-19. Scipher Medicine will present from London at 10 a.m. GMT on
- [Scipher Medicine<sup>®</sup> to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum](https://www.sciphermedicine.com/scipher-medicine-to-present-at-the-canaccord-genuity-virtual-medtech-diagnostics-and-digital-health-services-forum/) - November 10, 2021 - WALTHAM, Mass. - Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021, at
- [TARA Biosystems Partners with Scipher Medicine®](https://www.sciphermedicine.com/tara-biosystems-partners-with-scipher-medicine/) - Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform forcardiac laminopathies. Partnership set to reduce target discovery and validation from years down to months. NEW YORK, NY and WALTHAM, MA November 3, 2021: TARA Biosystems, a biotechnology company harnessing human biology and data
- [Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis](https://www.sciphermedicine.com/scipher-medicine-announces-publication-of-clinical-study-validating-prismra-a-blood-test-predicting-non-response-to-tnf-inhibitor-therapies-in-patients-with-rheumatoid-arthritis/) - PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results from the PrismRA clinical validation study. The publication titled “Clinical validation of a blood-based predictive test for
- [Scipher: Decoding Drug Response From Protein Interactions](https://www.sciphermedicine.com/scipher-decoding-drug-response-from-protein-interactions/) - Scipher aims to improve drug response predictions by incorporating protein interaction networks in its gene expression analysis algorithms. To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction map into its machine learning-based analyses of patient gene expression data to spotlight pathologically relevant markers. According to Scipher Medicine Corp. CEO Alif Saleh,
- [Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients](https://www.sciphermedicine.com/scipher-medicine-receives-medicare-coverage-for-prismra-test-in-rheumatoid-arthritis-patients/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”]WALTHAM, Mass., September 7, 2023 – Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor
- [Scipher Medicine Publishes New Data Further Supporting Clinical Utility of PrismRA Blood Test](https://www.sciphermedicine.com/scipher-medicine-publishes-new-data-further-supporting-clinical-utility-of-prismra-blood-test/) - Patients Show Nearly Two-fold Clinical Improvement when Treatment Selection Informed by PrismRA; Predictive Blood Test Could Improve Efficiency in Health Care Spending WALTHAM, Mass. (April 28, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new data showing patients with rheumatoid arthritis (RA) whose treatment was informed
- [America’s Choice Provider Network Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care](https://www.sciphermedicine.com/americas-choice-provider-network-partners-with-scipher-medicine-to-improve-patient-outcomes-and-lower-costs-for-rheumatoid-arthritis-care/) - Highlights:PrismRA® Blood Test Supports Personalized Treatment for RA PatientsImproves Clinical Outcomes for Rheumatoid Arthritis (RA) Patients. WALTHAM, Mass. (December 1, 2021) - Scipher Medicine, a precision immunology company matching patients with their most effective medication therapy, today announced a partnership with America’s Choice Provider Network (ACPN), an independent, multi-specialty national provider network, to offer ACPN customers access to PrismRA. PrismRA is the only blood test commercially available that informs personalized
- [Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time](https://www.sciphermedicine.com/scipher-medicine-acquires-crossbridge-and-its-saas-platform-to-collect-and-map-patient-molecular-outcomes-and-claims-data-in-real-time/) - [et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.
- [A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study](https://www.sciphermedicine.com/a-molecular-signature-response-classifier-to-predict-inadequate-response-to-tumor-necrosis-factor-α-inhibitors-the-network-004-prospective-observational-study/) - [et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]Stanley Cohen, Alvin F. Wells, Jeffrey R. Curtis, Rajat Dhar, Theodore Mellors, Lixia Zhang, Johanna B. Withers, Alex Jones, Susan D. Ghiassian, Mengran Wang, Erin Connolly-Strong, Sarah Rapisardo, Zoran Gatalica, Dimitrios A. Pappas, Joel M. Kremer, Alif Saleh & Viatcheslav R. Akmaev Rheumatol Ther 8, 1159–1176 (2021) Abstract: Objectives: Timely matching
- [Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis](https://www.sciphermedicine.com/patient-outcomes-improve-when-a-molecular-signature-test-guides-treatment-decision-making-in-rheumatoid-arthritis/) - [et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]Jeffrey R. Curtis; Vibeke Strand; Steven Golombek; Lixia Zhang; Angus Wong; Mark C. Zielinski; Viatcheslav R. Akmaev; Alif Saleh; Sam Asgarian; and Johanna B. Withers Background The molecular signature response classifier (MSRC) predicts tumor necrosis factor-ɑ inhibitor (TNFi) non-response in rheumatoid arthritis. This study evaluates decision-making, validity, and utility
- [Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis ](https://www.sciphermedicine.com/quest-diagnostics-collaborate-scipher-medicine/) - Relationship leverages Quest’s sequencing and specimen collection expertise with Scipher’s precision medicine technology SECAUCUS, NJ and WALTHAM, MA – November 28, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services
- [Scipher Medicine Signs Multi-Target Partnership with Ionis](https://www.sciphermedicine.com/scipher-medicine-signs-multi-target-partnership-with-ionis/) - Focus on development of precision therapeutics could lead to new and more effective treatments in disease areas including cardiovascular and CNS WALTHAM, Mass.--(July 17, 2023, BUSINESS WIRE)--Scipher Medicine today announced that it has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. In the collaboration, Ionis is responsible for advancing, developing and commercializing oligonucleotide therapies
- [Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study](https://www.sciphermedicine.com/scipher-medicine-announces-publication-of-positive-results-from-aims-clinical-study/) - Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass. (November 10, 2022) – Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients. The latest
- [Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis](https://www.sciphermedicine.com/evaluation-of-physician-global-assessment-in-patients-with-b-tsdmard-therapy-selection-aligned-with-a-molecular-signature-response-classifier-an-analysis-from-the-study-to-accelerate-information-of-m/) - Johanna Withers, PhD; Lixia Zhang, PhD; Sam Asgarian, MD Presented at EULAR 2022 Copenhagen, Denmark - June 1-4, 2022 Background: Despite drug therapies that improve lives, tens of millions of patients annually are subjected to therapy using a “trial-and-error” approach because, until recently, it was not possible to use a patient’s unique molecular profile to
- [Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform](https://www.sciphermedicine.com/galapagos-in-licenses-novel-drug-targets-for-inflammatory-bowel-disease-discovered-by-scipher-medicines-spectra-platform/) - Collaboration Achieves Key Milestones After Preclinical Validation Work, Triggers Milestone Payment to Scipher WALTHAM, Mass. (May 24, 2022) – Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra™ platform. In August 2020, Galapagos and Scipher Medicine agreed
- [Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium](https://www.sciphermedicine.com/scipher-medicine-to-participate-in-truist-securities-life-sciences-ai-symposium/) - WALTHAM, Mass. (Feb. 28, 2022) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities Life Sciences AI Symposium on Tuesday, March 1, 2022, at 10:10 a.m. ET. ### About Scipher Medicine
- [Scipher Medicine Lab Image](https://www.sciphermedicine.com/scipher-medicine-stat/) - Scipher_Medicine_STAT_ImageDownload
- [Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis ](https://www.sciphermedicine.com/budget-impact-and-clinical-outcomes-of-a-molecular-signature-to-inform-tnfi-treatment-selection-in-commercial-patients-with-rheumatoid-arthritis/) - Martin Bergman, MD; Erin Connolly-Strong, PhD; Alyssa Guidoboni, MScM; Alix Arnaud, MsC Presented at AMCP 2022 Chicago, Illinois - March 29, 2022 Introduction: • Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation. • With no established preference for one class of drug over the other after failure of conventional csDMARDs, current
- [Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis](https://www.sciphermedicine.com/network-based-response-module-comprised-of-gene-expression-biomarkers-predicts-response-to-infliximab-at-treatment-initiation-in-ulcerative-colitis/) - Susan D Ghiassian, PhD; Ivan Voitalov; Johanna B Withers, PhD; Marc Santolini; Alif Saleh; Viatcheslav R Akmaev, PhD Translational Research - The Journal of Laboratory and Clinical Medicine Abstract: Introduction: Ulcerative colitis (UC) is a chronic, relapsing disease characterized by diffuse mucosal inflammation of the colon. UC is part of a larger spectrum of chronic relapsing
- [Scipher Medicine Strengthens Leadership Team with Appointment of Sam A Davis, JD as General Counsel](https://www.sciphermedicine.com/scipher-medicine-strengthens-leadership-team-with-appointment-of-sam-a-davis-jd-as-general-counsel/) - SEPTEMBER 24, WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announces the appointment of Sam A. Davis, JD, as General Counsel. Sam will lead all legal matters, including strategic partnerships, future collaborations, and growth financing transactions, as the company enters its next stage of growth as a
- [Network medicine framework for identifying drug-repurposing opportunities for COVID-19](https://www.sciphermedicine.com/network-medicine-framework-for-identifying-drug-repurposing-opportunities-for-covid-19/) - Deisy Morselli Gysi, Ítalo do Valle, Marinka Zitnik, Asher Ameli, Xiao Gana, Onur Varola, Susan Dina Ghiassian, J. J. Patten, Robert A. Davey, Joseph Loscalzo, and Albert-László Barabási Proceedings of the National Academy of Sciences Abstract: Introduction: The disruptive nature of the COVID-19 pandemic has unveiled the need for the rapid development, testing, and deployment
- [A molecular signature response classifier stratifies seropositive rheumatoid arthritis patients based on their likelihood of inadequate response to TNF inhibitor therapies](https://www.sciphermedicine.com/a-molecular-signature-response-classifier-stratifies-seropositive-rheumatoid-arthritis-patients-based-on-their-likelihood-of-inadequate-response-to-tnf-inhibitor-therapies/) - Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR. Rheumatol Ther. 2021 Sep;8(3):1159-1176. Abstract: Introduction: Timely matching of patients to beneficial targeted therapy is an unmet need in rheumatoid arthritis
- [A high-confidence definition of therapeutic response in rheumatoid arthritiss using a Monte Carlo simulation approach](https://www.sciphermedicine.com/a-high-confidence-definition-of-therapeutic-response-in-rheumatoid-arthritiss-using-a-monte-carlo-simulation-approach/) - V. Strand, S. Cohen, L. Zhang, T. Mellors, A. Jones, J. Withers, V. Akmaev Annals of the Rheumatic Diseases 2021;80:1097-1098. Abstract: Background: Therapy choice and therapy change depend on the ability to accurately assess patients’ disease activity. The clinical assessments used to evaluate treatment response in rheumatoid arthritis have inherent variability, normally considered as measurement error,
- [A molecular signature response classifier predicts the likelihood of eular nonresponse to TNF inhibitor therapies in RA: results from a retrospective cohort analysis](https://www.sciphermedicine.com/a-molecular-signature-response-classifier-predicts-the-likelihood-of-eular-nonresponse-to-tnf-inhibitor-therapies-in-ra-results-from-a-retrospective-cohort-analysis/) - L. Zhang1 , C. van der Tog2 , A. den Broeder2 , T. Mellors1 , E. Connolly-Strong1 , J. Withers1 , A. Jones1 , V. Akmaev1 . 1 Scipher Medicine Corporation, Science and Technology, Waltham, United States of America; 2 Sint Maartenskliniek, Department of Rheumatology, Ubbergen, Netherlands hold Abstract: Background: Following RA treatment recommendations, most
- [A network medicine approach to discover common novel drug target mechanisms across autoimmune diseases](https://www.sciphermedicine.com/a-network-medicine-approach-to-discover-common-novel-drug-target-mechanisms-across-autoimmune-diseases/) - Ghiassian, Susan PhD; Withers, Johanna PhD; Akmaev, Viatcheslav PhD The American Journal of Gastroenterology: October 2021 - Volume 116 - Issue - p S431-S432 Abstract: Introduction: The map of human disease biology called the human interactome (HI) is a map of experimentally determined protein-protein interactions. Understanding the topology and dynamics of patient molecular data through
- [Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies](https://www.sciphermedicine.com/discontinuation-of-tnfi-treatment-among-rheumatoid-arthritis-patients-with-a-molecular-signature-of-non-response-to-tumor-necrosis-factor-a-inhibitor-therapies/) - Jeffrey Curtis, Joel Kremer, Dimitrios Pappas, Lixia Zhang, Erin Connolly-Strong, Johanna Withers, Viatcheslav Akmae and Alif Saleh Abstract: Background: A 23-feature blood-based molecular signature response classifier1 (MSRC) identifies rheumatoid arthritis (RA) patients who are unlikely to respond to tumor necrosis factor-ɑ inhibitor (TNFi) therapies. This study evaluated treatment outcomes over a 12-month period among patients prescribed
- [A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months](https://www.sciphermedicine.com/a-molecular-signature-response-classifier-predicts-the-likelihood-of-non-response-to-tnf-inhibitor-therapies-in-ra-at-3-months/) - Stanley Cohen, Theodore Mellors, Lixia Zhang, Alex Jones, Erin Connolly-Strong, Dimitrios Pappas, Joel Kremer, Johanna Withers and Viatcheslav Akmae ACR Convergence 2021 Abstract: Background: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor (TNFi) as their first targeted therapy. A blood-based molecular signature response classifier (MSRC) was shown to predict inadequate response to
- [PrismRA: a personalized medicine test that accurately predicts rheumatoid arthritis patients who will not respond adequately to tumor necrosis factor inhibitors](https://www.sciphermedicine.com/prismra-a-personalized-medicine-test-that-accurately-predicts-rheumatoid-arthritis-patients-who-will-not-respond-adequately-to-tumor-necrosis-factor-inhibitors/) - Keith Johnson, Nancy Schoenbrunner and Dina Ghiassian 2018 ACR/ARHP Annual Meeting Abstract: Background: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism achieves treatment targets in the majority of patients. Tumor necrosis factor inhibitors (anti-TNFs) are the first line therapy
- [A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study](https://www.sciphermedicine.com/a-systems-based-method-to-repurpose-marketed-therapeutics-for-antiviral-use-a-sars-cov-2-case-study/) - Mengran Wang, Johanna B Withers, Piero Ricchiuto, Ivan Voitalov, Michael McAnally, Helia N Sanchez, Alif Saleh, Viatcheslav R Akmaev, Susan Dina Ghiassian Abstract: Introduction: Viruses are obligate intracellular parasites that can only replicate by entering into a host cell and hijacking host cell machinery to produce and assemble new progeny virions. The arsenal to treat
- [Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study](https://www.sciphermedicine.com/perceived-clinical-utility-of-a-test-for-predicting-inadequate-response-to-tnf-inhibitor-therapies-in-rheumatoid-arthritis-results-from-a-decision-impact-study/) - Dimitrios A. Pappas, Christine Brittle, James E. Mossell III, Johanna B. Withers, Jeraldine Lim-Harashima & Joel M. Kremer Rheumatology International volume 41, pages585–593 (2021) Abstract: Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1.3 million U.S. adults [1]. When RA is not adequately controlled, joint damage and chronic inflammation can lead
- [Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis](https://www.sciphermedicine.com/clinical-utility-and-cost-savings-in-predicting-inadequate-response-to-anti-tnf-therapies-in-rheumatoid-arthritis/) - Martin J. Bergman, Alan J. Kivitz, Dimitrios A. Pappas, Joel M. Kremer, Lixia Zhang, Anna Jeter & Johanna B. Withers Rheumatology and Therapy volume 7, pages775–792 (2020) Abstract: Introduction: The PrismRA® test identifies rheumatoid arthritis (RA) patients who are unlikely to respond to anti-tumor necrosis factor (anti-TNF) therapies. This study evaluated the clinical and financial
- [Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis](https://www.sciphermedicine.com/analytical-and-clinical-validation-of-an-rna-sequencing-based-assay-for-quantitative-accurate-evaluation-of-a-molecular-signature-response-classifier-in-rheumatoid-arthritis/) - Alex Jones, Sarah Rapisardo, Lixia Zhang, Theodore Mellors, Johanna B. Withers, Zoran Gatalica, and Viatcheslav R. Akmaev Abstract: Objectives: This study reports analytical and clinical validation of a molecular signature response classifier (MSRC) that identifies rheumatoid arthritis (RA) patients who are non-responders to tumor necrosis factor-ɑ inhibitors (TNFi). Materials and Methods: The MSRC integrates patient-specific
- [Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility](https://www.sciphermedicine.com/guided-therapy-selection-in-rheumatoid-arthritis-using-a-molecular-signature-response-classifier-an-assessment-of-budget-impact-and-clinical-utility/) - Christopher Arnell, MBA; Martin Bergman, MD; Dhiman Basu, MD; James T Kenney, RPh, MBA; Johanna B Withers, PhD; Jennifer Logan, PhD; Jeraldine Lim Harashima, MS, CGC; and Erin Connolly-Strong, PhD J Manag Care Spec Pharm. 2021;27(12):1734-42 Abstract: Objectives: To model cost-effectiveness of MSRC-guided, first-line targeted therapy selection compared with current standard care. Materials and Methods:
- [Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis](https://www.sciphermedicine.com/clinical-utility-of-therapy-selection-informed-by-predicted-nonresponse-to-tumor-necrosis-factor-a-inhibitors-an-analysis-from-the-study-to-accelerate-information-of-molecular-signatures-aims-in-rh/) - Vibeke Strand, Stanley B. Cohen, Jeffrey R. Curtis, Lixia Zhang, Alan J. Kivitz, Robert W. Levin, Angela Mathis, Erin Connolly-Strong, and Johanna B. Withers Expert Review of Molecular Diagnostics 2021, VOL. 22, NO. 1, 101-109 Abstract: Objectives: The molecular signature response classifier (MSRC) is a blood-based precision medicine test that predicts nonresponders to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA) so that patients with a molecular signature of non-response to
- [Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients](https://www.sciphermedicine.com/clinical-validation-of-a-blood-based-predictive-test-for-stratification-of-response-to-tumor-necrosis-factor-inhibitor-therapies-in-rheumatoid-arthritis-patients/) - Theodore Mellors, Johanna B. Withers, Asher Ameli, Alex Jones, Mengran Wang, Lixia Zhang, Helia N. Sanchez, Marc Santolini, Italo Do Valle, Michael Sebek, Feixiong Cheng, Dimitrios A. Pappas, Joel M. Kremer, Jeffery R. Curtis, Keith J. Johnson, Alif Saleh, Susan D. Ghiassian, and Viatcheslav R. Akmaev Network and Systems Medicine Volume 3.1, 2020 DOI: 10.1089/nsm.2020.0007
- [Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago](https://www.sciphermedicine.com/nearly-15-of-prescribing-u-s-rheumatologists-use-scipher-medicines-prismra-blood-test-since-its-launch-a-year-ago/) - PrismRA enables precision medicine, supports better outcomes, and reduces ineffective utilization of TNFi therapy for rheumatoid arthritis treatment WALTHAM, Mass. (December 6, 2021) – Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced that nearly 15 percent of prescribing U.S. rheumatologists have used PrismRA since its launch a year
- [Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA Blood Test](https://www.sciphermedicine.com/scipher-medicine-announces-publication-of-real-world-study-demonstrating-clinical-utility-of-prismra-blood-test/) - Patient Response to Treatment 3x Better When PrismRA Guided Therapy Selection Test Results Informed Treatment Decisions for Three-Quarters of Patients Broad Adoption Could Lead to Significant Clinical Improvements for Rheumatoid Arthritis Patients WALTHAM, Mass. (Feb. 1, 2022) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new
- [Scipher Medicine Closes $110 Million Financing](https://www.sciphermedicine.com/scipher-medicine-closes-110-million-financing/) - Cowen Healthcare Investments leads the round Additional new investors include Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management Returning investors include Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Innovation Alliance, and Alumni Ventures WALTHAM, Mass. (Feb. 24, 2022) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy,
- [Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference](https://www.sciphermedicine.com/scipher-medicine-leadership-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/) - WALTHAM, Mass. (Jan. 6, 2022) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Alif Saleh, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:30 a.m. ET. Conference participants can view the presentation through J.P. Morgan’s EventCenter. About Scipher Medicine® Scipher Medicine, a
- [COVID-19 might be bitter medicine for what ails AI investing](https://www.sciphermedicine.com/covid-19-might-be-bitter-medicine-for-what-ails-ai-investing/) - Silicon AngleR. Danes Is investor belt-tightening brought on by COVID-19 the bitter medicine needed to bring sanity to the artificial intelligence funding bubble, flush out fakes, and shift venture capitalists’ attention to the most deserving companies? In 2019, private investments in AI totaled over $70 billion, with startups taking $37 billion of that. Despite these figures, AI in
- [Scipher Medicine Increases Patient Access for PrismRA<sup>®</sup> by Expanding Intended Use in Autoimmune Patients](https://www.sciphermedicine.com/scipher-medicine-increases-patient-access-for-prismra-by-expanding-intended-use-in-autoimmune-patients/) - Expanded intended use for the blood test validated in Network-004 study.Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.Test enables providers to identify optimal rheumatoid arthritis treatment for more than 600,000 patients annually. July 29, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with the
- [Developing New Drug Treatments in the Era of Network Medicine](https://www.sciphermedicine.com/developing-new-drug-treatments-in-the-era-of-network-medicine/) - Published in American Society for Clinical Pharmacology & Therapeutics Clin Pharmacol Ther. Author manuscript; available in PMC 2013 January 15.Published in final edited form as:Clin Pharmacol Ther. 2013 January ; 93(1): 26–28. doi:10.1038/clpt.2012.207. Authors: Edwin K. Silverman, M.D., Ph.D. and Joseph Loscalzo, M.D., Ph.D. Although impressive advances have been made in determining the genetic and molecular causes of
- [Network-based in silico drug efficacy screening](https://www.sciphermedicine.com/network-based-in-silico-drug-efficacy-screening/) - Published in Nature Communications Authors: Emre Guney, Jörg Menche, Marc Vidal, & Albert-László Barábasi NATURE COMMUNICATIONS | 7:10331 | DOI: 10.1038/ncomms10331 |www.nature.com/naturecommunications The increasing cost of drug development together with a significant drop in the number of new drug approvals raises the need for innovative approaches for target identification and efficacy prediction. Here, we take advantage of our increasing understanding
- [GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis](https://www.sciphermedicine.com/gns-healthcare-and-scipher-medicine-collaborate-to-develop-worlds-first-in-silico-patient-for-rheumatoid-arthritis/) - – Partnership leverages Scipher Medicine’s proprietary patient clinico-genomic data – In silico patient models enable pharmaceutical companies to understand what disease treatments work for which patients and why SOMERVILLE, Mass. & WALTHAM, Mass.- GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, and Scipher Medicine, a precision immunology company matching patients
- [Reduce Wasted Spend While Significantly Improving Clinical Outcomes](https://www.sciphermedicine.com/reduce-wasted-spend-while-significantly-improving-clinical-outcomes/) - 55 million RA patients do not respond to the drugs they are prescribed daily by physicians, dictated by formulary requirements. By prescribing these ineffective medications, we waste billions of dollars, and patients cycle through multiple treatment plans, delaying improvement. Scipher Medicine has created a platform and toolset to determine a patient's best and most effective
- [Who is Scipher Medicine?](https://www.sciphermedicine.com/who-is-scipher-medicine/) - Scipher Medicine believes patients with autoimmune diseases deserve a simple answer to their treatment plan using scientifically backed data. By applying network medicine to its platform, we are developing diagnostic tests to identify patients who will not respond to the world's largest selling drugs so that they can be prescribed alternative therapies. We then take
- [Integrating personalized gene expression profiles into predictive disease-associated gene pools](https://www.sciphermedicine.com/integrating-personalized-gene-expression-profiles-into-predictive-disease-associated-gene-pools/) - Published in Nature: NJP Systems Biology and Applications Authors: Jörg Menche, Emre Guney, Amitabh Sharma, Patrick J. Branigan, Matthew J. Loza, Frédéric Baribaud, Radu Dobrin & Albert-László Barábasi npj Systems Biology and Applications (2017) 3:10 ; doi:10.1038/s41540-017-0009-0 Gene expression data are routinely used to identify genes that on average exhibit different expression levels between a case and a control group. Yet, very few
- [A DIseAse MOdule Detection (DIAMOnD) Algorithm Derived from a Systematic Analysis of Connectivity Patterns of Disease Proteins in the Human Interactome](https://www.sciphermedicine.com/human-interactome/) - Susan Dina Ghiassian, Jörg Menche, Albert-László Barabási PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004120 April 8, 2015 Abstract The observation that disease associated proteins often interact with each other has fueled the development of network-based approaches to elucidate the molecular mechanisms of human disease. Such approaches build on the assumption that protein interaction networks can be viewed
- [A Proteome-Scale Map of the Human Interactome Network](https://www.sciphermedicine.com/protein-interactions/) - Thomas Rolland, Murat Tasxan, Benoit Charloteaux, Samuel J. Pevzner, Quan Zhong, Nidhi Sahni, Song Yi, Irma Lemmens, Celia Fontanillo, Roberto Mosca, Atanas Kamburov, Susan D. Ghiassian, Xinping Yang, Lila Ghamsari, Dawit Balcha, Bridget E. Begg, Pascal Braun, Marc Brehme, Martin P. Broly, Anne-Ruxandra Carvunis, Dan Convery-Zupan, Roser Corominas, Jasmin Coulombe-Huntington, Elizabeth Dann, Matija Dreze, Ame´
- [Uncovering disease-disease relationships through the incomplete interactome](https://www.sciphermedicine.com/uncovering-disease-disease-relationships-through-the-incomplete-interactome/) - Authors: Jörg Menche, Amitabh Sharma, Maksim Kitsak, S. Dina Ghiassian, Marc Vidal, Joseph Loscalzo, Albert-László Barabási sciencemag.org 20 FEBRUARY 2015 • VOL 347 ISSUE 6224 Introduction A disease is rarely a straightforward consequence of an abnormality in a single gene, but rather reflects the interplay of multiple molecular processes. The relationships among these processes are encoded in the interactome, a network
- [A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in Asthma](https://www.sciphermedicine.com/a-disease-module-in-the-interactome-explains-disease-heterogeneity-drug-response-and-captures-novel-pathways-and-genes-in-asthma/) - Amitabh Sharma1,2,3,†, Jörg Menche1,2,4,8,†, C. Chris Huang5, Tatiana Ort5, Xiaobo Zhou3, Maksim Kitsak1,2, Nidhi Sahni2, Derek Thibault3, Linh Voung3, Feng Guo3, Susan Dina Ghiassian1,2, Natali Gulbahce6, Frédéric Baribaud5, Joel Tocker5, Radu Dobrin5, Elliot Barnathan5, Hao Liu5, Reynold A. Panettieri Jr7, Kelan G. Tantisira3, Weiliang Qiu3, Benjamin A. Raby3, Edwin K. Silverman3, Marc Vidal2,9, Scott T.
- [Tissue Specificity of Human Disease Module](https://www.sciphermedicine.com/tissue-specificity-of-human-disease-module/) - Maksim Kitsak1,2, Amitabh Sharma1,2,3, Jörg Menche1,2,4,5, Emre Guney1,2,6, Susan Dina Ghiassian1,2,7, Joseph Loscalzo8 & Albert-László Barabási1,2,4,7,8,9 Genes carrying mutations associated with genetic diseases are present in all human cells; yet, clinical manifestations of genetic diseases are usually highly tissue-specific. Although some disease genes are expressed only in selected tissues, the expression patterns of disease genes
- [Scipher Medicine Reports Positive Results for Prism](https://www.sciphermedicine.com/scipher-medicine-reports-positive-results-for-prism-a-drug-response-test/) - Prism could save the health insurance industry $20 billion by avoiding paying for ineffective therapies. This test was developed to meet a medical and financial need for patients with autoimmune diseases.
- [Khosla Ventures backs Scipher Medicine to bring precision medicine to autoimmune diseases](https://www.sciphermedicine.com/khosla-ventures-backs-scipher-medicine-to-bring-precision-medicine-to-autoimmune-diseases/) - WALTHAM, Mass., Sept. 6, 2018 /PRNewswire/ -- Scipher Medicine, developer of a molecular technology platform that can predict if a patient will actually respond to a particular drug therapy announced today that it has completed its Series A round led by Khosla Ventures. With this investment, total funds raised by the company to date are $10 million. Over 65%
- [Use Of The PrismRA Test To Stratify Patients For Response To Anti-TNF Therapy In RA](https://www.sciphermedicine.com/use-of-the-prismra-test-to-stratify-patients-for-response-to-anti-tnf-therapy-in-ra/) - Scipher's CSO Keith Johnson, PhD and Michael Weinblatt, MD discuss the importance of extending precision medicine from oncology to complex diseases by using PrismRA, a drug response test, to stratify patients based on drugs that are more likely to work adequately for them.
- [Scipher Medicine Builds Evidence for Tests Predicting Response to Autoimmune Disease Drugs](https://www.sciphermedicine.com/scipher-medicine-builds-evidence-for-tests-predicting-response-to-autoimmune-disease-drugs/) - Published by GenomeWeb Scipher Medicine of Boston is hoping to develop molecular signatures that can predict a patient's response to autoimmune disease drugs, pushing precision medicine into areas other than oncology. The company, which was founded in 2014 by researchers at Northeastern University, Harvard, and Brigham and Women's Hospital, uses a proprietary approach for discovering
- [Deciphering RNA to Predict if a Patient Will Respond to a Targeted Drug](https://www.sciphermedicine.com/deciphering-rna-to-predict-if-a-patient-will-respond-to-a-targeted-drug/) - Scipher Medicine was featured in Technology Networks to discuss the power of RNA "Ineffective drugs have a profound impact on patients. First of all, the patient could be taking a medication that not only doesn't make them feel better, but could also result in unwanted adverse effects. Establishing a way to ensure patients are prescribed
- [Smart Medicine: AI plays an increasingly bigger role in health care](https://www.sciphermedicine.com/smart-medicine-ai-plays-an-increasingly-bigger-role-in-health-care/) - Boston Business Journal highlights local companies advancing healthcare using AI Artificial intelligence is changing healthcare from how we diagnose diseases, model drug development, and predict response to therapies. The Boston Business Journal names Scipher Medicine as one of the companies leading the way in this endeavor due to Prism's unique ability to understand various autoimmune
- [Bringing Precision Medicine to Autoimmune Diseases](https://www.sciphermedicine.com/bringing-precision-medicine-to-autoimmune-diseases/) - Shifting Precision Medicine from Oncology to Autoimmune Diseases The Bio Report featured a podcast about precision medicine in autoimmune diseases and spoke with Alif Saleh, CEO of Scipher, to learn more about how we use gene expression data, instead of DNA, to predict response to the world's largest selling drug class. We are taking the
- [Network-based prediction of drug combinations](https://www.sciphermedicine.com/network-based-prediction-of-drug-combinations/) - Feixiong Cheng1,2,3,4,5, István A. Kovács1,2 & Albert-László Barabási1,2,6,7 Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple complex diseases. Yet, our ability to identify and validate effective combinations is limited by a combinatorial explosion, driven by both the large number of drug pairs as well as dosage combinations.
- [Getting Personal With Precision Medicine](https://www.sciphermedicine.com/getting-personal-with-precision-medicine/) - The Precision Medicine Era PharmaVoice outlines why now is a new era of healthcare driven by precision medicine and how we got here, including the new trends in research to how we are moving these advancements out of research onto the market. Multiple leaders in pharmaceuticals, diagnostics, and research organizations were interviewed for this piece
- [Scipher Medicine Closes Series B Funding Led By Northpond Ventures](https://www.sciphermedicine.com/scipher-medicine-closes-series-b-funding-led-by-northpond-ventures/) - Technology to significantly improve outcomes for autoimmune disease patients by ensuring optimal therapy is prescribed from day one WALTHAM, MA – December 19, 2019—Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy from day one to improve patient outcomes, announced the completion of Series B financing
- [Scipher Medicine Announces Investment By Optum Ventures Focused on Improving Patient Outcomes](https://www.sciphermedicine.com/scipher-medicine-announces-investment-by-optum-ventures-focused-on-improving-patient-outcomes/) - Investment to Accelerate Molecular Diagnostic Product Selection, Development and Accessibility WALTHAM (February 19, 2020) — Scipher Medicine, a developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, announced an investment from Optum Ventures, the independent venture fund of Optum. Under the terms of the agreement, Optum Ventures has
- [Scipher Medicine Welcomes Chief Technology Officer](https://www.sciphermedicine.com/scipher-medicine-welcomes-chief-technology-officer/) - Appoints Slava Akmaev, Ph.D., as Chief Technology Officer WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava Akmaev, Ph.D. as Chief Technology Officer to the growing leadership team. As CTO, Dr. Akmaev will oversee the data science and technology
- [Scipher Medicine has developed a blood test expected to save payers billions each year](https://www.sciphermedicine.com/scipher-medicine-has-developed-a-blood-test-expected-to-save-payers-billions-each-year/) - Optum Ventures is among companies investing $25 million, betting on the company's ability to show for which patients Humira doesn't work. Healthcare Finance NewsSusan Morse, Managing Editor Humira is the top-selling prescription drug by revenue. The biologic drug is the first line of treatment on many formularies for treating rheumatoid arthritis, Crohn's disease and other autoimmune diseases.
- [Coronavirus: AI steps up in battle against Covid-19](https://www.sciphermedicine.com/coronavirus-ai-steps-up-in-battle-against-covid-19/) - BBCJane Wakefield, Technology Reporter Normally, just getting them all to work together would take "a year of paperwork", said Scipher's chief executive Alif Saleh. But a series of Zoom calls with a "group of people with a unprecedented determination to get things done, not to mention a lot of time of their hands", speeded things
- [Pandemic versus pandemonium: fighting on two fronts](https://www.sciphermedicine.com/pandemic-versus-pandemonium-fighting-on-two-fronts/) - The Lancet The ongoing COVID-19 pandemic has motivated many across the globe to adopt different approaches to understand the virus, surveil how the virus spreads, and search for effective treatments. This health crisis has focused global efforts on leveraging technology to fight the pandemic. Technological tools have undeniable strengths and hold great promise; however, under
- [Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease](https://www.sciphermedicine.com/scipher-medicine-and-galapagos-sign-collaboration-in-inflammatory-bowel-disease/) - -- Companies to jointly validate novel drug targets ---- Scipher eligible for upfront, opt-in and milestone payments ---- Galapagos to progress selected targets into drug discovery -- Mechelen, Belgium and Boston, USA; 12 August 2020 - Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused
- [New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis](https://www.sciphermedicine.com/new-strategy-for-avoiding-waste-and-improving-response-for-highest-cost-therapies-in-rheumatoid-arthritis/) - AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLCAlif Saleh, CEO, Scipher Medicine Drug costs for targeted autoimmune diseases account for a large and growing proportion of pharmacy spend per patient. Despite most rheumatoid arthritis patients receiving anti-TNF therapies as their first targeted treatment, 2 in 3 patients have
- [Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market](https://www.sciphermedicine.com/scipher-medicine-and-ambry-genetics-partner-to-bring-precision-medicine-test-for-rheumatoid-arthritis-to-market/) - PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory.Partnership provides infrastructure for rapid scaling and patient accessibility. SEPTEMBER 17, 2020- WALTHAM, MA, and ALISO VIEJO, CA – Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced a strategic partnership with leading clinical genetic and genomic testing laboratory Ambry Genetics. Both parties
- [New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients](https://www.sciphermedicine.com/new-study-demonstrates-clinical-utility-of-prismra-test-in-guiding-therapy-selection-for-rheumatoid-arthritis-patients/) - Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. - DECEMBER 7, 2020Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced findings from a clinical utility study published in Rheumatology International that the PrismRA® test can lead to major
- [Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative](https://www.sciphermedicine.com/scipher-medicine-brings-precision-medicine-platform-to-patient-centered-mit-initiative/) - First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021- WALTHAM, MA- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced today they have partnered with Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms Initiative (NEWDIGS) in their mission to enhance the capacity
- [WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care](https://www.sciphermedicine.com/welldyne-partners-with-scipher-medicine-to-improve-patient-outcomes-and-lower-costs-for-rheumatoid-arthritis-care/) - New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 - WALTHAM, MA - Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with WellDyne, a full-service, independent pharmacy benefit manager (PBM) that is bringing precision medicine into their decision-making,
- [Understanding protein interaction to optimize drug discovery](https://www.sciphermedicine.com/understanding-protein-interaction-to-optimize-drug-discovery/) - Blog 01 Bret S. Stetka, MD The human genome contains over 20,000 genes. And every single one of these encodes for a protein that has some function in our body. But just as crucial to both health and disease is how these proteins interact with each other: how they collaborate to drive specific biological processes,
- [Addressing wasted healthcare dollars and ineffective prescriptions](https://www.sciphermedicine.com/addressing-wasted-healthcare-dollars-and-ineffective-prescriptions/) - Blog 02 Bret S. Stetka, MD A recent review published in JAMA reported that the annual monetary waste in the U.S. healthcare system is approaching a staggering 1 trillion dollars. Over half of this is due to patients being prescribed drugs that they don’t actually respond to. Much of the spending on medications is also
- [Scipher Medicine Announces $82 Million Financing](https://www.sciphermedicine.com/scipher-medicine-announces-82-million-financing/) - -aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine PrismTM portfolio of blood tests and data partnerships in autoimmune diseases with payers, providers and pharma. MARCH 24, 2021 – WALTHAM, MA – Scipher Medicine®, a precision immunology company matching patients with
- [A Conversation with Scipher Medicine Chief Technology Officer Slava Akmaev](https://www.sciphermedicine.com/a-conversation-with-scipher-medicine-chief-technology-officer-slava-akmaev/) - Blog 03 Bret S. Stetka, MD Medicine is often a guessing game. Doctors frequently prescribe medications that, while effective across the collective population, may not work for specific individuals. This is why so many clinicians are studying and advocating for personalized medicine; or matching the right patients with the right medications based on their individual
- [Scipher Applies Spectra<sup>TM</sup> Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies](https://www.sciphermedicine.com/scipher-applies-spectra-platform-to-discover-drugs-targeting-autoimmune-patients-refractory-to-existing-therapies/) - - Leverages large genomic database from Scipher’s testing business- Proven SpectraTM platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships. MAY 4, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced the launch of Scipher Therapeutics, focused on discovering new targets
- [Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify Covid-19 Treatments from Years to Months](https://www.sciphermedicine.com/scipher-medicine-and-leading-medical-researchers-in-network-and-data-science-compress-time-to-identify-covid-19-treatments-from-years-to-months-2/) - Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune diseases. June 8, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with the most effective therapy, in collaboration with Northeastern University; Brigham and Women’s Hospital, Harvard Medical School, and Boston
- [Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA<sup>®</sup> Test](https://www.sciphermedicine.com/scipher-medicine-presents-new-data-at-the-european-league-against-rheumatism-eular-2021-further-validating-prismra-test/) - Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohortPrismRA demonstrates a more efficient therapy selection protocol beyond current standardThree new analyses published on efficacy of PrismRA test stratification in patients with rheumatoid arthritis at EULAR JUNE 15, 2021 – WALTHAM, MA
- [Scipher Medicine Announces PrismRA<sup>®</sup> Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class, TNFi](https://www.sciphermedicine.com/scipher-medicine-announces-prismra-met-primary-and-secondary-endpoints-in-prospective-observational-study-predicting-inadequate-response-to-worlds-largest-selling-drug-class-tnfi/) - Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with TherapyProviders Can Access Patient-Specific Data for Optimized Therapy Selection JUNE 24, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced positive results from a multicenter, blinded prospective observational clinical study assessing the ability
- [Scipher Medicine Translates Complex Biology to Predict Better Outcomes](https://www.sciphermedicine.com/scipher-medicine-translates-complex-biology-to-predict-better-outcomes/) - Blog 4 Researchers at Scipher Medicine have combined proprietary data and artificial intelligence to predict a patient’s response to costly biologics. Slava Akmaev, Ph.D., Scipher Chief Technology Officer and Head of Therapeutics describes the implications of their new study, Network-004 that demonstrates the ability of PrismRA® to identify anti-tumor necrosis factor inhibitor (TNFi) therapy non-responders
- [In RA, New Molecular Signature Test Confirms Who Won’t Respond to Anti-TNF Therapy During Any Point in Therapeutic Journey](https://www.sciphermedicine.com/in-ra-new-molecular-signature-test-confirms-who-wont-respond-to-anti-tnf-therapy-during-any-point-in-therapeutic-journey/) - Blog 06 Q&A with Erin Connolly-Strong PhD, Head Medical Affairs Scipher Medicine via BiopharmaDive Multiple classes of drugs exist for treating rheumatoid arthritis (RA) patients. But close to 90% of patients failing methotrexate are prescribed the world’s largest selling drug class, tumor necrosis factor-α inhibitor (TNFi) therapies – even though the majority don’t respond adequately.
- [Can a Blood-Based Test Predict TNFi Nonresponse in RA?](https://www.sciphermedicine.com/can-a-blood-based-test-predict-tnfi-nonresponse-in-ra/) - Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to predict nonresponse to tumor necrosis factor inhibitors as treatment for rheumatoid arthritis, an observational clinical study has found, but the test’s predictive accuracy was well below 100%. The test is the blood-based molecular signature response classifier
- [New Partnership Delivers Precision Medicine to Pharmacy Benefits Managers](https://www.sciphermedicine.com/new-partnership-delivers-precision-medicine-to-pharmacy-benefits-managers/) - Blog 07 via RxSense Specialty drug spending contributes the largest share to rising healthcare costs. To make matters worse, in the case of rheumatoid arthritis, most patients will, over time, become refractory to these specialty biologics. In some cases, this may happen because the patients develop antibodies to, for example, tumor necrosis factor inhibitors (TNFi), but in
- [Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways](https://www.sciphermedicine.com/trellis-rx-furthers-commitment-to-advancing-the-specialty-pharmacy-practice-and-patient-outcomes-with-integration-of-scipher-medicine-prismra-precision-medicine-technology-into-clinical-pa/) - October 12, 2021, Atlanta, GA and Waltham, MA – Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the integration of PrismRA, a diagnostic blood test created by Scipher Medicine that predicts non-response to TNF Inhibitor (TNFi) therapies, into its clinical pathway for patients living with rheumatoid arthritis (RA). Scipher Medicine, the manufacturer of
- [Ventegra Partners with Scipher Medicine For Patient-Centric Approach To Improve Outcomes and Lower Costs for Rheumatoid Arthritis Care](https://www.sciphermedicine.com/ventegra-partners-with-scipher-medicine-for-patient-centric-approach-to-improve-outcomes-and-lower-costs-for-rheumatoid-arthritis-care/) - SEPTEMBER 16, 2021 – WALTHAM, MA Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with Ventegra, Inc., a new class-of-trade Medical Benefits Manager that uses innovative programs and products to ensure appropriate use of prescription drugs while lowering clients’ costs. The partnership will enable Ventegra to offer its

## Pages

- [Homepage](https://www.sciphermedicine.com/) - [et_pb_section fb_built=”1″ admin_label=”Hero” _builder_version=”4.24.2″ _module_preset=”default” background_color=”#1B1235″ background_image=”https://www.sciphermedicine.com/wp-content/uploads/2024/02/Group-42.png” background_position=”center_right” background_video_mp4=”https://www.sciphermedicine.com/wp-content/uploads/2024/02/Header_Sequencer01_compressed.mp4″ height=”640px” height_tablet=”” height_phone=”450px” height_last_edited=”on|phone” custom_margin=”0px||||false|false” custom_padding=”||||false|false” scroll_blur_enable=”on” scroll_blur=”0|40|60|100|0px|0px|10px” motion_trigger_start=”bottom” background_last_edited=”on|phone” use_background_color_gradient_phone=”on” background_color_gradient_direction_phone=”90deg” background_color_gradient_stops_phone=”rgba(51,31,82,0.63) 0%|rgba(35,21,56,0.75) 72%|rgba(1,1,10,0) 100%” background_color_gradient_overlays_image_phone=”on” background_horizontal_offset_phone=”25%” background_video_mp4_phone=”https://www.sciphermedicine.com/wp-content/uploads/2024/02/Header_Sequencer01_compressed.mp4″ background_enable_video_mp4_phone=”on” global_colors_info=”{}”][et_pb_row make_equal=”on” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” height=”100%” custom_margin=”||||false|false” scroll_horizontal_motion=”0|50|50|100|0|0|-4″ motion_trigger_start=”bottom” global_colors_info=”{}”][et_pb_column type=”4_4″ admin_label=”Hero Text” _builder_version=”4.24.0″ _module_preset=”default” custom_css_main_element=”margin: auto;” global_colors_info=”{}”][et_pb_image src=”https://www.sciphermedicine.com/wp-content/uploads/2024/02/Group-72.png” title_text=”Group 72″ _builder_version=”4.24.2″ _module_preset=”default” width=”13.1%” custom_margin=”|||10px|false|false” custom_margin_tablet=”|||10px|false|false”
- [Solutions](https://www.sciphermedicine.com/solutions/) - [et_pb_section fb_built=”1″ custom_padding_last_edited=”on|phone” admin_label=”Hero” _builder_version=”4.24.2″ _module_preset=”default” background_color=”#331F52″ background_image=”https://www.sciphermedicine.com/wp-content/uploads/2024/04/dot_US_map.svg” background_size=”initial” background_position=”top_center” background_vertical_offset=”25%” background_enable_video_mp4=”off” height=”770px” height_tablet=”600px” height_phone=”” height_last_edited=”on|phone” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” custom_padding_tablet=”0px||||false|false” custom_padding_phone=”0px||0px||false|false” motion_trigger_start=”bottom” background_last_edited=”on|phone” background_enable_video_mp4_phone=”off” global_colors_info=”{}”][et_pb_row make_equal=”on” custom_padding_last_edited=”on|phone” _builder_version=”4.24.0″ _module_preset=”default” positioning=”none” width_tablet=”” width_phone=”100%” width_last_edited=”on|phone” custom_margin_tablet=”-5px||||false|false” custom_margin_phone=”-5px||||false|false” custom_margin_last_edited=”on|tablet” custom_padding=”9.9%||||false|false” custom_padding_tablet=”” custom_padding_phone=”3.5em|1.5em|3.5em|1.5em|true|true” scroll_horizontal_motion=”0|50|50|100|0|0|-4″ motion_trigger_start=”bottom” global_colors_info=”{}”][et_pb_column type=”4_4″ admin_label=”Hero Text” _builder_version=”4.24.0″ _module_preset=”default” custom_css_main_element=”margin: auto;” global_colors_info=”{}”][et_pb_text admin_label=”As Many” _builder_version=”4.24.0″ _module_preset=”d4fb185a-636e-44d7-be19-9a4c21a370db” global_colors_info=”{}”] As
- [Company](https://www.sciphermedicine.com/company/) - [et_pb_section fb_built=”1″ admin_label=”Hero” _builder_version=”4.24.0″ _module_preset=”default” background_color=”#331F52″ background_image=”https://www.sciphermedicine.com/wp-content/uploads/2024/02/dots-left.svg” background_size=”custom” background_position=”bottom_left” background_horizontal_offset=”-12%” background_enable_video_mp4=”off” height=”400px” height_tablet=”” height_phone=”auto” height_last_edited=”on|tablet” custom_margin=”0px||||false|false” scroll_blur_enable=”on” scroll_blur=”0|40|60|100|0px|0px|10px” motion_trigger_start=”bottom” background_last_edited=”on|phone” background_enable_video_mp4_phone=”off” custom_css_after=” content: ”;|| position: absolute;|| top: 0;|| right: -13%;|| width: 50%; /* Adjust the width as needed */|| height: 100%;|| background-image: url(‘/wp-content/uploads/2024/02/dots-right.svg’);|| background-position: center right;|| background-repeat: no-repeat;|| background-size: actual; /* Adjust as needed */||
- [Privacy Policy](https://www.sciphermedicine.com/privacy-policy/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_fullwidth_header title=”Legal and Privacy” _builder_version=”4.24.0″ _module_preset=”aeb14945-ba15-4ed4-8572-5cd39942e6c3″ global_colors_info=”{}”][/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”7278c7c7-5c94-425f-8e57-409e6088cc1d” custom_padding=”5px|||||” global_colors_info=”{}”] QUICK NAVIGATION [/et_pb_text][et_pb_text _builder_version=”4.24.2″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” hover_enabled=”0″ custom_css_free_form=”.selector ul {|| margin-left: 20px;||}||||.selector a {|| color: #B52670;||}||||.selector h2 {|| font-family: ‘Bebas Neue’,display;|| font-size: 28px;|| letter-spacing: 3.6px;|| margin-top: 1.5em;|| color: #331F52;||}”
- [Careers](https://www.sciphermedicine.com/careers/) - [et_pb_section fb_built=”1″ admin_label=”Hero” _builder_version=”4.24.0″ _module_preset=”default” background_color=”#331F52″ background_image=”https://www.sciphermedicine.com/wp-content/uploads/2024/03/Image-35.jpg” background_blend=”luminosity” background_enable_video_mp4=”off” height=”400px” height_tablet=”” height_phone=”auto” height_last_edited=”on|tablet” custom_margin=”0px||||false|false” scroll_blur_enable=”on” scroll_blur=”0|40|60|100|0px|0px|10px” motion_trigger_start=”bottom” background_last_edited=”on|tablet” background_enable_video_mp4_phone=”off” locked=”off” global_colors_info=”{}”][et_pb_row make_equal=”on” _builder_version=”4.24.0″ _module_preset=”default” width=”100%” height=”100%” custom_margin=”||||false|false” scroll_horizontal_motion=”0|50|50|100|0|0|-4″ motion_trigger_start=”bottom” global_colors_info=”{}”][et_pb_column type=”4_4″ admin_label=”Hero Text” _builder_version=”4.24.0″ _module_preset=”default” custom_css_main_element=”margin: auto;” global_colors_info=”{}”][et_pb_text admin_label=”As Many” _builder_version=”4.24.0″ _module_preset=”d4fb185a-636e-44d7-be19-9a4c21a370db” text_text_color=”#F1CE8B” global_colors_info=”{}”] CAREERS [/et_pb_text][et_pb_text admin_label=”50 Mil” _builder_version=”4.24.0″ _module_preset=”ad5561ed-de14-4dd9-8ad6-aaa9f7a4e870″ global_colors_info=”{}”] WHO WE ARE [/et_pb_text][et_pb_text
- [Resources](https://www.sciphermedicine.com/resources/) - [et_pb_section fb_built=”1″ admin_label=”Resources Filter” _builder_version=”4.24.0″ _module_preset=”default” background_color=”gcid-a059579c-0b37-413a-8474-9c64da0bf2c2″ locked=”off” global_colors_info=”{%22gcid-a059579c-0b37-413a-8474-9c64da0bf2c2%22:%91%22background_color%22%93}”][et_pb_row admin_label=”Text & Code/CSS 4 Tabs” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code admin_label=”JS Code Tabs” _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][/et_pb_code][et_pb_code admin_label=”JS Code Articles” _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”] [/et_pb_code][et_pb_code admin_label=”CSS for Tabs” _builder_version=”4.24.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] [/et_pb_code][et_pb_code admin_label=”CSS for Articles” _builder_version=”4.24.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] [/et_pb_code][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ use_custom_gutter=”on” gutter_width=”1″
- [Contact Us](https://www.sciphermedicine.com/contact/) - [et_pb_section fb_built=”1″ admin_label=”Hero” module_id=”testing-divi-id” _builder_version=”4.24.0″ _module_preset=”default” background_color=”#331F52″ background_enable_image=”off” background_size=”custom” background_position=”bottom_left” background_horizontal_offset=”-12%” background_enable_video_mp4=”off” height=”240px” height_tablet=”776px” height_phone=”auto” height_last_edited=”on|phone” custom_margin=”0px||||false|false” scroll_blur=”0|40|60|100|0px|0px|10px” motion_trigger_start=”bottom” background_last_edited=”on|phone” background_enable_video_mp4_phone=”off” locked=”off” global_colors_info=”{}”][et_pb_row make_equal=”on” _builder_version=”4.24.0″ _module_preset=”default” width=”100%” height=”100%” custom_padding=”0px||0px||false|false” scroll_horizontal_motion=”0|50|50|100|0|0|-4″ motion_trigger_start=”bottom” global_colors_info=”{}”][et_pb_column type=”4_4″ admin_label=”Hero Text” _builder_version=”4.24.0″ _module_preset=”default” custom_css_main_element=”margin: auto;” global_colors_info=”{}”][et_pb_text admin_label=”As Many” _builder_version=”4.24.0″ _module_preset=”d4fb185a-636e-44d7-be19-9a4c21a370db” header_2_text_color=”#B52670″ global_colors_info=”{}”] CONTACT US [/et_pb_text][et_pb_text admin_label=”People Suffer” _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” text_text_color=”#FFFFFF” text_orientation=”center”
- [Become a Partner](https://www.sciphermedicine.com/become-a-partner/) - [et_pb_section fb_built=”1″ admin_label=”Hero” module_id=”testing-divi-id” _builder_version=”4.24.0″ _module_preset=”default” background_color=”#331F52″ background_enable_image=”off” background_size=”custom” background_position=”bottom_left” background_horizontal_offset=”-12%” background_enable_video_mp4=”off” height=”240px” height_tablet=”776px” height_phone=”auto” height_last_edited=”on|phone” custom_margin=”0px||||false|false” scroll_blur=”0|40|60|100|0px|0px|10px” motion_trigger_start=”bottom” background_last_edited=”on|phone” background_enable_video_mp4_phone=”off” locked=”off” global_colors_info=”{}”][et_pb_row make_equal=”on” _builder_version=”4.24.0″ _module_preset=”default” width=”100%” height=”100%” custom_padding=”0px||0px||false|false” scroll_horizontal_motion=”0|50|50|100|0|0|-4″ motion_trigger_start=”bottom” global_colors_info=”{}”][et_pb_column type=”4_4″ admin_label=”Hero Text” _builder_version=”4.24.0″ _module_preset=”default” custom_css_main_element=”margin: auto;” global_colors_info=”{}”][et_pb_text admin_label=”As Many” _builder_version=”4.24.0″ _module_preset=”d4fb185a-636e-44d7-be19-9a4c21a370db” header_2_text_color=”#B52670″ global_colors_info=”{}”] Become a partner [/et_pb_text][et_pb_text admin_label=”People Suffer” _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” text_text_color=”#FFFFFF”
- [Notice of Nondiscrimination](https://www.sciphermedicine.com/notice-of-nondiscrimination/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_fullwidth_header title=”Notice of Nondiscrimination” _builder_version=”4.24.0″ _module_preset=”aeb14945-ba15-4ed4-8572-5cd39942e6c3″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” custom_css_free_form=”.selector ul {|| margin-left: 20px;||}||||.selector a {|| color: #B52670;||}||||.selector h2 {|| font-family: ‘Bebas Neue’,display;|| font-size: 28px;|| letter-spacing: 3.6px;|| margin-top: 1.5em;|| color: #331F52;||}” global_colors_info=”{}”] Notice of Nondiscrimination Discrimination
- [Section 1557 Nondiscrimination Notice](https://www.sciphermedicine.com/section-1557-nondiscrimination-notice/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_fullwidth_header title=”Section 1557 Nondiscrimation Notice” _builder_version=”4.24.0″ _module_preset=”aeb14945-ba15-4ed4-8572-5cd39942e6c3″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” custom_css_free_form=”.selector ul {|| margin-left: 20px;||}||||.selector a {|| color: #B52670;||}||||.selector h2 {|| font-family: ‘Bebas Neue’,display;|| font-size: 28px;|| letter-spacing: 3.6px;|| margin-top: 1.5em;|| color: #331F52;||}” global_colors_info=”{}”] Section 1557 Nondiscrimination
- [Careers](https://www.sciphermedicine.com/careers-placeholder/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_fullwidth_header title=”Careers” _builder_version=”4.24.0″ _module_preset=”aeb14945-ba15-4ed4-8572-5cd39942e6c3″ global_colors_info=”{}” theme_builder_area=”post_content”]Placeholder content[/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.0″ _module_preset=”6ae41db7-2f4b-4c6e-abca-eb04a80e8814″ global_colors_info=”{}” theme_builder_area=”post_content”]Who We Are[/et_pb_text][et_pb_text _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” global_colors_info=”{}” theme_builder_area=”post_content”]Placeholder text.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.0″ _module_preset=”6ae41db7-2f4b-4c6e-abca-eb04a80e8814″ global_colors_info=”{}”
- [Legal](https://www.sciphermedicine.com/legal/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_fullwidth_header title=”Legal” _builder_version=”4.24.0″ _module_preset=”aeb14945-ba15-4ed4-8572-5cd39942e6c3″ global_colors_info=”{}” theme_builder_area=”post_content”] Placeholder content [/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.0″ _module_preset=”6ae41db7-2f4b-4c6e-abca-eb04a80e8814″ global_colors_info=”{}” theme_builder_area=”post_content”] Terms, Policies, & Practices [/et_pb_text][et_pb_text _builder_version=”4.24.0″ _module_preset=”e0f1d194-1be6-4f55-9616-090bdacde9ce” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″] Privacy Policy Patient Opt-out Information Notice of Privacy Practices Terms of
- [Home (Old)](https://www.sciphermedicine.com/home/)
- [Platform](https://www.sciphermedicine.com/platform/) - A Decade of Research Built upon over a decade of experimental research, the platform’s backbone is the network map of human biology explaining how proteins expressed from the human genome interact to cause specific disease phenotypes, providing the wiring diagram needed to interpret dynamic individual patient molecular data to reveal actual disease biology. Not a
- [Platform Science](https://www.sciphermedicine.com/platform/platform-science/)
- [Site Map](https://www.sciphermedicine.com/site-map/)

## Team Members

- [Courtney Morris](https://www.sciphermedicine.com/team/courtney-morris/) - Previous Post Next Post
- [Ryan Phan](https://www.sciphermedicine.com/team/ryan-phan-2/) - Previous Post
- [Mridula Iyer](https://www.sciphermedicine.com/team/al-karim-rehemtula-2/) - Previous Post Next Post
- [Mridula Iyer](https://www.sciphermedicine.com/team/al-karim-rehemtula-2/) - Previous Post Next Post
- [Keiko Mitsunobu](https://www.sciphermedicine.com/team/keiko-mitsunobu-2/) - Previous Post Next Post
- [Stefan Krieglstein](https://www.sciphermedicine.com/team/adam-seltser/) - Previous Post Next Post
- [Dina Ghiassian](https://www.sciphermedicine.com/team/dina-ghiassian/) - Previous Post Next Post
- [Steve Liapis](https://www.sciphermedicine.com/team/steve-liapis-2/) - Previous Post Next Post
- [Slava Akmaev](https://www.sciphermedicine.com/team/slava-akmaev-phd/) - Previous Post Next Post
- [Derek Woodward](https://www.sciphermedicine.com/team/derek-woodward-2/)
- [Reginald Seeto](https://www.sciphermedicine.com/team/reginald-seeto/) - Previous Post Next Post
- [Chris Younger](https://www.sciphermedicine.com/team/chris-younger/) - Previous Post Next Post
- [Todd Sone](https://www.sciphermedicine.com/team/todd-sone/) - Previous Post Next Post
- [Joseph Loscalzo](https://www.sciphermedicine.com/team/joseph-loscalzo/) - Previous Post Next Post
- [Samir Kaul](https://www.sciphermedicine.com/team/samir-kaul/) - Previous Post Next Post
- [Albert-László Barabási](https://www.sciphermedicine.com/team/albert-laszlo-barabasi/) - Previous Post Next Post
- [Timothy Anderson](https://www.sciphermedicine.com/team/timothy-anderson/) - Previous Post Next Post
- [Lixia Zhang](https://www.sciphermedicine.com/team/lixia-zhang/) - Previous Post Next Post
- [Laura Mitz](https://www.sciphermedicine.com/team/laura-mitz/) - Previous Post Next Post
- [Emily Kerwin](https://www.sciphermedicine.com/team/emily-kerwin/) - Previous Post Next Post
- [Alex Jones](https://www.sciphermedicine.com/team/alex-jones/) - Previous Post Next Post
- [Sherry A Guardiano](https://www.sciphermedicine.com/team/sherry-a-guardiano/) - Previous Post Next Post
- [Stacey Kaufman](https://www.sciphermedicine.com/team/stacey-kaufman/) - Previous Post Next Post
- [April Cobb](https://www.sciphermedicine.com/team/april-cobb/) - Next Post

## Timeline Events

- [2024](https://www.sciphermedicine.com/timeline-event/2024/)
- [2015](https://www.sciphermedicine.com/timeline-event/2015/)
- [2013](https://www.sciphermedicine.com/timeline-event/2013/)
- [2022](https://www.sciphermedicine.com/timeline-event/2022/)
- [2021](https://www.sciphermedicine.com/timeline-event/2021/)
- [2019](https://www.sciphermedicine.com/timeline-event/2019/)
- [2018](https://www.sciphermedicine.com/timeline-event/2018/)
- [2003](https://www.sciphermedicine.com/timeline-event/2003/)
- [2023](https://www.sciphermedicine.com/timeline-event/2023/)
- [2020](https://www.sciphermedicine.com/timeline-event/2020/)

## Categories

- [Press releases](https://www.sciphermedicine.com/category/press-releases/)
- [News articles](https://www.sciphermedicine.com/category/news-articles/)
- [Publications](https://www.sciphermedicine.com/category/publications/)
- [Blog](https://www.sciphermedicine.com/category/blog/)
- [Videos](https://www.sciphermedicine.com/category/videos/)
- [Papers](https://www.sciphermedicine.com/category/papers/)
- [Media Kit](https://www.sciphermedicine.com/category/media-kit/)

## Tags

- [PrismRA](https://www.sciphermedicine.com/tag/prismra/)
- [Power of RNA](https://www.sciphermedicine.com/tag/power-of-rna/)
- [Precision Medicine](https://www.sciphermedicine.com/tag/precision-medicine/)
- [gene expression](https://www.sciphermedicine.com/tag/gene-expression/)
- [Drug Discovery](https://www.sciphermedicine.com/tag/drug-discovery/)
- [Network Medicine](https://www.sciphermedicine.com/tag/network-medicine/)
- [artificial intelligence](https://www.sciphermedicine.com/tag/artificial-intelligence/)
- [White Paper](https://www.sciphermedicine.com/tag/white-paper/)
- [Spectra](https://www.sciphermedicine.com/tag/spectra/)
- [Clinical Trial](https://www.sciphermedicine.com/tag/clinical-trial/)